


- 9 -

Claims

1. A stent comprising one or more compounds of the formula (I)



5

in which

V is O,

Q is CH₂,

10

Y is phenyl which is substituted by a radical which is selected from the group consisting of 2-phenylethyl, cyclohexyl, 4-chlorophenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 4-cyanophenyl, 4-chlorophenoxy, 4-methoxyphenoxy, 4-trifluoromethylphenoxy, 4-cyanophenoxy, 4-methylphenyl,

15

R³ is hydrogen or fluorine,

m is an integer from 1 to 2,

20

W is -CH₂CH₂-,

U is -CH₂-,

25

A is phenyl,

- 10 -

R² is COOH, where R₂ is disposed in the 4-position relative to the radical U,

X is (CH₂)₄,


5

R¹ is COOH,

and the pharmaceutically acceptable salts, hydrates and/or mixtures thereof.

10 2. The stent as claimed in claim 1, characterized in that the compound of the formula (I) is

4-[((4carboxybutyl)-{2-[{(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]-benzoic acid hydrochloride




15

or

4-[((4carboxybutyl)-{2-[{(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid

- 11 -



3. The stent as claimed in claim 1 or 2, which is coated with an additional membrane.
- 5 4. The stent as claimed in any of claims 1 to 3, comprising at least one further active ingredient.
5. The stent as claimed in any of claims 1 to 4 for the treatment and/or prophylaxis of restenoses following PTCA.
- 10 6. The stent as claimed in any of claims 1 to 4 for the treatment and/or prophylaxis of thromboses following PTCA.
- 15 7. The use of compounds of the formula (I) as defined in claim 1 for or in the production of stents.
8. The use of compounds of the formula (I) as defined in claim 1 for producing stents for the treatment and/or prophylaxis of restenoses and/or thromboses.
- 20 9. A process for producing stents, characterized in that stents are coated or filled with one or more compounds of the formula (I) as defined in claim 1.
- 10 10. A process for producing stents, characterized in that polymeric carrier

materials comprising one or more compounds of the formula (I) as defined in claim 1 are shaped to stents.

11. A method for treating patients with restenotic arteries by simultaneous use of
5 one or more compounds of the formula (I) as defined in claim 1, and of a stent.
12. The method as claimed in claim 11, characterized in that compounds of the formula (I) as defined in claim 1 are present in or on the stent and are released
10 locally.
13. A method for the treatment and/or prophylaxis of restenoses and/or thromboses by using stents as claimed in any of the preceding claims in combination with local and/or systemic administration of other active
15 ingredients suitable for the treatment and/or prophylaxis of restenosis and/or thrombosis.
14. A method for the treatment and/or prophylaxis of restenoses and/or thromboses by using stents as claimed in any of the preceding claims in combination with systemic administration of compounds of the formula (I) as
20 defined in claim 1.